Which telehealth services still offer compounded GLP-1s after the FDA crackdown?

The landscape for compounded GLP-1s, especially semaglutide and tirzepatide, via telehealth has significantly shifted due to increased scrutiny from the FDA and state pharmacy boards. The FDA has repeatedly warned against the use of compounded versions of these drugs, primarily because:

1. Safety and Efficacy Concerns: Compounded drugs are not FDA-approved and have not undergone the rigorous testing for safety, efficacy, and quality control that brand-name drugs have.
2. Availability of Approved Drugs: A key justification for compounding is when an FDA-approved drug is on a shortage list. While specific dosages of Ozempic/Wegovy/Mounjaro/Zepbound can experience temporary shortages, the FDA has stated that the active ingredients (semaglutide and tirzepatide) are generally available, undermining the primary legal basis for compounding identical versions.
3. Ingredient Concerns: The FDA has specifically warned against compounded versions made with salt forms of semaglutide (e.g., semaglutide sodium, semaglutide acetate), as these are not the same active ingredient used in the approved drugs and their safety and efficacy are unknown.

What This Means for Telehealth Services:

Many reputable telehealth services that previously offered compounded GLP-1s have either:

• Stopped offering them entirely to avoid legal and regulatory risks.
• Significantly scaled back or limited their use to only very specific, medically necessary circumstances (e.g., documented allergy to an inactive ingredient in the brand-name drug, or a verified, long-term unavailability of an exact dosage that cannot be otherwise replicated).
• Transitioned to primarily prescribing the brand-name, FDA-approved versions (Ozempic, Wegovy, Mounjaro, Zepbound), with the understanding that cost and insurance coverage remain significant barriers for many patients.

It's crucial to understand that actively seeking out services that market compounded GLP-1s without strong medical justification carries potential risks. Be highly skeptical of services that:

• Aggressively promote "cheap" compounded versions.
• Don't require a thorough medical evaluation.
• Don't clearly state the source of their compounded medications.

Which Telehealth Services Might Still Facilitate Access (with extreme caution):

It's difficult to name specific services that still openly and primarily market compounded GLP-1s, as many have changed their practices. Instead, focus on reputable weight management telehealth platforms. If they offer compounded options, it would likely be under strict medical necessity and not as a primary offering for everyone.

Here are types of services and what to look for:

1. Major Telehealth Weight Management Platforms (Primarily Prescribe FDA-Approved):

   • WW Clinic (formerly Sequence): Focuses on comprehensive weight management, including prescribing FDA-approved GLP-1s. They emphasize working with insurance.
   • Calibrate: Similar comprehensive approach, focusing on FDA-approved GLP-1s, metabolic health, and coaching.
   • Found: Offers personalized weight care, including medication management and coaching, often emphasizing FDA-approved options.
   • Ro Body/PlushCare: These broader telehealth platforms can prescribe GLP-1s for qualified patients, generally focusing on FDA-approved versions.

   Why they are relevant: While their primary focus is on FDA-approved drugs, if a legitimate medical reason arises (e.g., a patient cannot tolerate an ingredient in the brand-name drug, or there's a verified, specific dosage shortage that prevents proper treatment), some may have established relationships with compounding pharmacies that adhere to stricter standards. However, this would be the exception, not the rule, for semaglutide and tirzepatide.

2. Smaller, Independent Telehealth Providers or Clinics:

   • You might find independent medical practices or smaller telehealth clinics that still work with compounding pharmacies.
   • Why to be cautious: It's paramount to vet these thoroughly.
     • Ask: Where does the compounding pharmacy source its ingredients? Is it a 503A (traditional compounding) or 503B (outsourcing facility) pharmacy? (503B facilities have stricter FDA oversight).
     • Verify: Check the pharmacy's licensing and any disciplinary actions with state boards.
     • Demand Transparency: Insist on knowing the exact ingredients (avoid salt forms for semaglutide/tirzepatide unless specifically prescribed for a different, non-GLP-1 purpose) and the quality control processes.

Recommendation:

Given the current regulatory environment and safety concerns, my primary recommendation is to prioritize consulting with a healthcare professional (via telehealth or in-person) who will prescribe FDA-approved GLP-1 medications if medically appropriate.

If considering a compounded GLP-1, you must:

• Understand the Justification: There should be a clear, documented medical reason why an FDA-approved version cannot be used.
• Verify the Pharmacy: Ensure the compounding pharmacy is state-licensed, has a good reputation, and ideally operates as a 503B outsourcing facility or has robust quality control for 503A compounding.
• Know the Ingredients: Insist on knowing the exact active ingredient (not a salt form if it's meant to be identical to the approved drug) and all inactive ingredients.
• Discuss Risks: Have a thorough discussion with your prescribing provider about the knowns and unknowns of using a compounded medication.

The FDA's stance is clear: compounded versions of semaglutide and tirzepatide are not FDA-approved, and consumers should be wary. Always prioritize safety and efficacy with prescription medications.